AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7753895 — intervention group
Group type: COMPARATOR
Intervention: Coffee C (untreated from Europe)
Number of subjects: 20
Study 2487552 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (nonselective beta-blocker)
Number of subjects: 86
Study 2487552 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (benzodiazepine)
Number of subjects: 86
Study 2487552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 656294 — intervention group
Group type: EXPERIMENTAL
Intervention: delta1-tetrahydrocannabinol (delta1-THC) administered in 62 microliter metered volumes containing 50-200 microgram by inhalation from an aerosol device
Number of subjects: 1
Study 31968988 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 0
Study 31968988 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture (SA)
Number of subjects: 0
Study 31968988 — intervention group
Group type: COMPARATOR
Intervention: Placebo-acupuncture (PA)
Number of subjects: 0
Study 31968988 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study 31046016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of 0.01% atropine and +2.50‐diopter add center‐distance soft bifocal contact lenses (SBCL) for 2 weeks
Number of subjects: 49
Study 28536730 — intervention group
Group type: EXPERIMENTAL
Intervention: Climate heliotherapy (CHT) for 3 weeks
Number of subjects: 163
Study 25962165 — intervention group
Group type: EXPERIMENTAL
Intervention: BG00010 (neublastin, artemin, enovin) 0.3, 1, 3, 10, 25, 50, 100, 200, 400, or 800 μg/kg (intravenous) or 50 μg/kg (subcutaneous)
Number of subjects: 48
Study 25962165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25962165 — intervention group
Group type: EXPERIMENTAL
Intervention: BG00010
Number of subjects: 48
Study 25489146 — intervention group
Group type: EXPERIMENTAL
Intervention: S-POP classification system
Number of subjects: 100
Study 25489146 — intervention group
Group type: COMPARATOR
Intervention: POPQ classification system
Number of subjects: 100
Study 22370319 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin/gemcitabine (PCG)
Number of subjects: 626
Study 22370319 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin (GC)
Number of subjects: 626
Study 19029093 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose followed by bolus (0.06+0.94 mg kg(‐1))
Number of subjects: 90
Study 19029093 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg kg(‐1) bolus
Number of subjects: 90
Study 19029093 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg kg(‐1) bolus
Number of subjects: 90
Study 17308317 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily)
Number of subjects: 27
Study 17308317 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg daily)
Number of subjects: 27
Study 15033251 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF-1697 (0.1 microg/kg/min)
Number of subjects: 402
Study 15033251 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF-1697 (1.0 microg/kg/min)
Number of subjects: 402
Study 15033251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 15033251 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF-1697 (0.5 microg/kg/min)
Number of subjects: 402
Study 15033251 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF-1697 (2.0 microg/kg/min)
Number of subjects: 402
Study 15033251 — intervention group
Group type: EXPERIMENTAL
Intervention: All ITF-1697 dosages
Number of subjects: 402
Study 11695068 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg and calcium 1000 mg
Number of subjects: 151
Study 11695068 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 100 IU and calcium 1000 mg
Number of subjects: 151
Study 11695068 — intervention group
Group type: COMPARATOR
Intervention: Calcium 1000 mg
Number of subjects: 151
Study 9892908 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol/vehicle
Number of subjects: 699
Study 9892908 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol
Number of subjects: 699
Study 9892908 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol/clobetasone 17‐butyrate
Number of subjects: 699
Study 9892908 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone 17‐valerate
Number of subjects: 699
Study 8069886 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF dentifrice brushed three times daily
Number of subjects: 28
Study 8069886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing device (FRD; 0.07 mg F/day) plus F‐free dentifrice
Number of subjects: 28
Study 8069886 — intervention group
Group type: EXPERIMENTAL
Intervention: FRD (0.232 mg F/day) plus F‐free dentifrice
Number of subjects: 28
Study 8069886 — intervention group
Group type: EXPERIMENTAL
Intervention: FRD (0.232 mg F/day) plus NaF dentifrice
Number of subjects: 28
Study 8069886 — intervention group
Group type: COMPARATOR
Intervention: F‐free dentifrice three times daily
Number of subjects: 28
Study 2495079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg
Number of subjects: 20
Study 2495079 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 20
Study 2495079 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 75 mg combined with Warfarin
Number of subjects: 20
Study 794726 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 370
Study 31153882 — intervention group
Group type: EXPERIMENTAL
Intervention: Early TIPS (within 72 hours after initial endoscopy)
Number of subjects: 132
Study 31153882 — intervention group
Group type: EXPERIMENTAL
Intervention: Early TIPS
Number of subjects: 132
Study 31153882 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment with vasoactive drugs and endoscopic band ligation)
Number of subjects: 132
Study 31153882 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 27576370 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (10 mg/kg/day starting dose, increased to 15 and 20 mg/kg/day in some patients)
Number of subjects: 26
Study 27576370 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy (6 ml/kg/2 weeks)
Number of subjects: 26
Study 27576370 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (for patients with baseline serum ferritin 1,000 ng/ml or higher)
Number of subjects: 26
Study 27576370 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy (for patients with baseline serum ferritin 1,000 ng/ml or higher)
Number of subjects: 26
Study 27576370 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox and Phlebotomy (in patients with severe cardiac siderosis)
Number of subjects: 26
Study 27576370 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 26
Study 27576370 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 26
Study 26598476 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (switched from initial medication)
Number of subjects: 379
Study 26598476 — intervention group
Group type: COMPARATOR
Intervention: Lithium (switched from initial medication)
Number of subjects: 379
Study 26598476 — intervention group
Group type: COMPARATOR
Intervention: Divalproex (switched from initial medication)
Number of subjects: 379
Study 26598476 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (add-on for partial responders)
Number of subjects: 379
Study 26598476 — intervention group
Group type: COMPARATOR
Intervention: Divalproex (add-on for partial responders)
Number of subjects: 379
Study 26598476 — intervention group
Group type: COMPARATOR
Intervention: Lithium (add-on for partial responders)
Number of subjects: 379
Study 26598476 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (kg) for lithium add-on
Number of subjects: 379
Study 26598476 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (kg) for risperidone add-on
Number of subjects: 379
Study 26598476 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (kg) for divalproex add-on
Number of subjects: 379
Study 26598476 — intervention group
Group type: COMPARATOR
Intervention: Average weight gain comparison
Number of subjects: 379
Study 23391764 — intervention group
Group type: EXPERIMENTAL
Intervention: DP-b99
Number of subjects: 446
Study 23391764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study 22152181 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral tablet
Number of subjects: 1583
Study 22152181 — intervention group
Group type: EXPERIMENTAL
Intervention: Once every 6 months subcutaneous injection
Number of subjects: 1583
Study 22152181 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 1583
Study 19201093 — intervention group
Group type: EXPERIMENTAL
Intervention: pain re‐training
Number of subjects: 104
Study 19201093 — intervention group
Group type: COMPARATOR
Intervention: neutral re‐training
Number of subjects: 104
Study 19201093 — intervention group
Group type: EXPERIMENTAL
Intervention: threat induction
Number of subjects: 104
Study 19201093 — intervention group
Group type: COMPARATOR
Intervention: threat alleviation
Number of subjects: 104
Study 17989371 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 17
Study 15582920 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (16, 32 and 48 mg)
Number of subjects: 10
Study 15582920 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine (8, 16 and 24 mg)
Number of subjects: 10
Study 15582920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11465622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 100
Study 11465622 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic Intubation (FIB)
Number of subjects: 100
Study 9494477 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective evaluation of motion graded on a five-point scale by two radiologists
Number of subjects: 109
Study 9494477 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measurements of motion determined by computer reconstruction of the rod in three dimensions
Number of subjects: 109
Study 8306751 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 (0.2 mg dose)
Number of subjects: 16
Study 3377930 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg meptazinol suppository
Number of subjects: 15
Study 3377930 — intervention group
Group type: COMPARATOR
Intervention: 10 mg morphine i.m.
Number of subjects: 15
Study 31765004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led education-based intervention to deprescribe inappropriate medications (sedative-hypnotics, first-generation antihistamines, selective nonsteroidal anti-inflammatory drugs, glyburide)
Number of subjects: 19144
Study 31765004 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose aspirin (100 mg) for primary prevention
Number of subjects: 19144
Study 31765004 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergic exposure
Number of subjects: 19144
Study 31765004 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medications
Number of subjects: 19144
Study 30020342 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 15
Study 30020342 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 15
Study 26929616 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive behavior therapy (CBT)
Number of subjects: 0
Study 26929616 — intervention group
Group type: COMPARATOR
Intervention: Befriending (active social control)
Number of subjects: 0
Study 25163649 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin coconut oil (VCO) supplementation
Number of subjects: 60
Study 25163649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VCO supplementation)
Number of subjects: 60
Study 22520519 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Health encouragements (SMS, Internet, and mobile applications) delivered once a week for 1 year
Number of subjects: 216
Study 22520519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 216
Study 19015230 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 13558
Study 19015230 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 13558
Study 19015230 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 13558
Study 19015230 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive symptoms
Number of subjects: 13558
Study 19015230 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative symptoms
Number of subjects: 13558
Study 17673816 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP-14 + Rituximab (CEOP-R)
Number of subjects: 196
Study 17673816 — intervention group
Group type: COMPARATOR
Intervention: CEOP-14
Number of subjects: 196
Study 15068420 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II H. pylori
Number of subjects: 45
Study 12537652 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 101
Study 12537652 — intervention group
Group type: COMPARATOR
Intervention: Physician education
Number of subjects: 101
Study 12537652 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseled patients
Number of subjects: 101
Study 12537652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tested patients
Number of subjects: 101
Study 9825123 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytopharmaceutical
Number of subjects: 0
Study 9825123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8209992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral infra‐orbital local anaesthetic nerve blocks
Number of subjects: 20
Study 8209992 — intervention group
Group type: COMPARATOR
Intervention: Bilateral 'sham' blocks
Number of subjects: 20
Study 2658609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (1 gm)
Number of subjects: 260
Study 2658609 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (1 gm)
Number of subjects: 260
Study 2658609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 260
Study 2658609 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 260
Study 2658609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole and Cefotaxime
Number of subjects: 260
Study 30640138 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (RP) 25,000 IU per day for six months
Number of subjects: 36
Study 30640138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 28431432 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg total macular carotenoids
Number of subjects: 59
Study 28431432 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg total macular carotenoids
Number of subjects: 59
Study 28431432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 25510442 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg per day)
Number of subjects: 70
Study 25510442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22706694 — intervention group
Group type: COMPARATOR
Intervention: modified Story Memory Technique (mSMT)
Number of subjects: 0
Study 22706694 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 22545165 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of facial flies
Number of subjects: 24536
Study 22545165 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of formal education completed by the head of household
Number of subjects: 24536
Study 22545165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal discharge
Number of subjects: 24536
Study 22545165 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of flies on the face
Number of subjects: 24536
Study 19624626 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 4.0 microg.kg(‐1) co-administered with propofol 2.5 mg.kg(‐1)
Number of subjects: 90
Study 19624626 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1, 2, 3, 4, or 5 microg.kg(‐1) co-administered with propofol 2.5 mg.kg(‐1)
Number of subjects: 90
Study 17332198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 300
Study 17332198 — intervention group
Group type: COMPARATOR
Intervention: Codeine (1 mg/kg)
Number of subjects: 300
Study 17332198 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (15 mg/kg)
Number of subjects: 300
Study 15492182 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-enriched cellular graft applied to one lesion
Number of subjects: 28
Study 15492182 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to the paired lesion
Number of subjects: 28
Study 11767272 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of physostigmine (100 microl, 2-8 mg/ml) for 1 min in healthy subjects
Number of subjects: 20
Study 11767272 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse solution of physostigmine (10 ml, 0.4-1.6 mg/ml) for 2 min in dry-mouth patients
Number of subjects: 20
Study 9247512 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation present
Number of subjects: 40381
Study 8516307 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐697,661 25 mg twice a day
Number of subjects: 0
Study 8516307 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐697,661 100 mg three times a day
Number of subjects: 0
Study 8516307 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐697,661 500 mg twice a day
Number of subjects: 0
Study 8516307 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 100 mg five times a day
Number of subjects: 0
Study 8516307 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐697,661
Number of subjects: 0
Study 3802717 — intervention group
Group type: COMPARATOR
Intervention: Acute ethanol administration
Number of subjects: 0
Study 29701039 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhiyang (GV 9) Bazhen points combined with pantoprazole (40 mg once a day)
Number of subjects: 102
Study 29701039 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole (40 mg once a day)
Number of subjects: 102
Study 26684478 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Mindfulness-Based Stress Reduction (MBSR) program
Number of subjects: 300
Study 26684478 — intervention group
Group type: COMPARATOR
Intervention: Health Education (Healthy Topics [HT]) program
Number of subjects: 300
Study 25666481 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy (artificial amniotomy at cervical dilation <4 cm)
Number of subjects: 300
Study 25666481 — intervention group
Group type: COMPARATOR
Intervention: Routine management (control group)
Number of subjects: 300
Study 23521561 — intervention group
Group type: EXPERIMENTAL
Intervention: Humectant-rich formulation (15% alfahydroxy acids and 15% urea) applied once and twice daily
Number of subjects: 62
Study 23521561 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 62
Study 19882105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TURP and inguinal hernioplasty in the same session (Group I)
Number of subjects: 30
Study 19882105 — intervention group
Group type: COMPARATOR
Intervention: TURP followed by inguinal hernioplasty in separate sessions (Group II)
Number of subjects: 30
Study 18194559 — intervention group
Group type: EXPERIMENTAL
Intervention: Agenda-setting intervention for physicians
Number of subjects: 21
Study 18194559 — intervention group
Group type: COMPARATOR
Intervention: Control group physicians
Number of subjects: 21
Study 16766606 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies involving both partners simultaneously
Number of subjects: 0
Study 16766606 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment teams consisting of men and women
Number of subjects: 0
Study 12955553 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential hyperhidrosis patients (EH)
Number of subjects: 19
Study 12955553 — intervention group
Group type: COMPARATOR
Intervention: Controls with normal ANS function
Number of subjects: 19
Study 12955553 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential hyperhidrosis patients (EH) during tilt test
Number of subjects: 19
Study 12955553 — intervention group
Group type: COMPARATOR
Intervention: Controls during tilt test
Number of subjects: 19
Study 10968851 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 5 mg
Number of subjects: 67
Study 10968851 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 67
Study 9343031 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy
Number of subjects: 274
Study 9343031 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 274
Study 8372265 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous diclofenac
Number of subjects: 20
Study 8372265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 2425755 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 19
Study 2425755 — intervention group
Group type: COMPARATOR
Intervention: UVA plus placebo
Number of subjects: 19
Study 31599084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor infusion via peripheral venous catheters (PVC)
Number of subjects: 937
Study 31599084 — intervention group
Group type: COMPARATOR
Intervention: Vasopressor infusion via central venous catheters (CVC)
Number of subjects: 937
Study 30364005 — intervention group
Group type: EXPERIMENTAL
Intervention: GWG intervention based on an energy balance model
Number of subjects: 17
Study 27881335 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Qigong Wuqinxi training for 12 weeks
Number of subjects: 58
Study 24216342 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact immediately after birth
Number of subjects: 114
Study 24216342 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 114
Study 24216342 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 114
Study 22516476 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist Control Ventilation (ACV)
Number of subjects: 36